The final, formatted version of the article will be published soon.
CASE REPORT article
Front. Trop. Dis.
Sec. Neglected Tropical Diseases
Volume 5 - 2024 |
doi: 10.3389/fitd.2024.1372267
This article is part of the Research Topic Morbidity Management of Lymphatic Filariasis: A Focus on Filarial Hydrocele and Lymphoedema View all 4 articles
A LARGE FILARIAL HYDROCELE IN KENYA: A CASE REPORT
Provisionally acceptedMorbidity Management and Disability Prevention (MMDP) remains a key aspect of the Global project for the Elimination of Lymphatic Filariasis (GPELF) a program launched by WHO in the year 2000. In line with this mandate the Ministry of Health in Kenya having already achieved 95% Mass Drug Administration (MDA) by use of door-to-door drug administration (DA-albendazole and diethylcarbamazine) yearly for 5 years. The dosages used were albendazole 400mg and diethylcarbamazine citrate 6mg/Kg orally. Three drug combination by adding ivermectin (150ug/Kg) have been used in areas where the success of DA was suboptimal following the recommendation by WHO to speed up the elimination of lymphatic filariasis and areas endemic with onchocerciasis. A training workshop for surgeons and medical officers was organized in May 2023 for the surgical management of lymphatic hydroceles in the Coastal region of Kenya which is an endemic area for lymphatic filariasis. During the index training workshop in Kilifi, we encountered and managed an 83-year-old male who lived with a large grade 4 hydrocele and a right inguinal hernia for over six decades. We share our experience with this case report in this manuscript (large bilateral filarial hydrocele and right inguinal hernia for a period of sixty years. The objective of writing this report is to share our experience and the progress of MMDP program in Kenya.
Keywords: lymphatic filariasis, Capacity Building, Filarial hydrocelectomy technique, filarial hydrocele, MMDP (Morbidity Management and Disability Preventionn, MDA (Mass Drug Administration), Coastal region of Kenya, Wuchereria bancrofti
Received: 17 Jan 2024; Accepted: 30 Oct 2024.
Copyright: © 2024 . This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.